Case Reports:
Epidermal growth factor receptormutant lung cancer in Down syndrome: a case presentation and review of the literature
PDF | Full Text | How to cite
Metrics: PDF 1882 views | Full Text 2959 views
Xin Li1, Shijiang Xing1 and Qiumei Dong2
1Department of Medical Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, China
2Department of Medical Oncology, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
Correspondence to:
Qiumei Dong, email: [email protected]
Keywords: Down syndrome, non-small-cell lung cancer, EGFR mutation, trisomy 21, EGFR-TKIs resistance
Received: February 07, 2017 Accepted: April 03, 2017 Published: April 25, 2017
ABSTRACT
Background: Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.
Methods: The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.
Results: In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.
Conclusions: Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.